BCMA bispecific antibodies and BCMA CAR-T-cell therapy share the common goal of targeting BCMA-expressing myeloma cells, albeit through distinct mechanisms with unique characteristics. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.